Sponsored by
***FOR IMMEDIATE RELEASE***
CONTACT:
Paul Arndt, Corporate Communications Manager
parndt@neophrm.com
847-295-8678 x 215
(CNS)
Who/What: NeoPharm, Inc. (Nasdaq/NM: NEOL) cintredekin besudotox (IL13-PE38QQR) poster presentation
Why: Preliminary safety and tolerability data for cintredekin besudotox in the treatment of newly-diagnosed malignant glioma
Where: Hynes Convention Center
Digital Poster Center, Exhibit Hall D, 2nd Floor
Boston, MA
When: Monday, October 10 9:00 a.m. – 4:30 p.m.
Tuesday, October 11 9:00 a.m. – 4:30 p.m.
Wednesday, October 12 9:00 a.m. – 4:00 p.m.
Electronic Poster Format
Posters can be searched by Author, Name, or Title
Title: Convection-Enhanced Delivery of Cintredekin Besudotox (IL13-PE38QQR) Followed by Radiation Therapy without and with Temozolomide: A Phase I Study in Newly-Diagnosed Malignant Glioma Patients
Authors: Michael A. Vogelbaum, MD, PhD, John H. Sampson, MD, PhD, Sandeep Kunwar MD, Susan Chang, MD, Fredrick F. Lang, MD, Mark E. Shaffrey, MD, Anthony L. Asher, MD, David Croteau, MD, Kristen Parker, BS, Jeanne L. Dul, PhD, Jeffrey W. Sherman, MD, FACP, Raj K. Puri, MD, PhD
About NeoPharm, Inc.
NeoPharm, Inc., based in Lake Forest, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a portfolio of cancer compounds in various stages of development. Additional information can be obtained by visiting NeoPharm's Website at: www.neophrm.com.